Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meclinertant maintenance in extensive stage SCLC
NCT00290953Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2002
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Meclinertant Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival. Started Oct 2002; status: completed.
02
Drugs
meclinertant
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00290953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290953.